Skip to main content

Table 2 Metabolic control and QALY for the study population at baseline and after 48 weeks of insulin analog therapy

From: Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study

 

Trial arms

BIAsp 30 (n = 82)

NPH/Reg Insulin (n = 82)

 

Baseline

48 weeks

P value

Baseline

48 weeks

P value

HbA1c (%)

9.55 ± 1.03

7.15 ± 0.24

0.021

9.97 ± 1.52

7.62 ± 0.21

0.011

FPG (mg/dl)

208.10 ± 4.51

144.33 ± 8.16

0.029

185.76 ± 12.1

132.00 ± 13.2

0.027

PPG (mg/dl)

276.84 ± 9.2

211.51 ± 10.3

0.032

239.25 ± 12.55

180.88 ± 12.90

0.019

TG (mg/dl)

183.19 ± 11.33

173.44 ± 12.50

0.247

191.22 ± 55.11

170.42 ± 40.18

0.631

Total Chol (mg/dl)

184.41 ± 21.31

169.41 ± 15.13

0.471

176.33 ± 22.30

161.28 ± 18.34

0.259

LDL (mg/dl)

103.72 ± 19.70

101.89 ± 16.42

0.554

110.39 ± 14.56

98.44 ± 19.45

0.131

HDL (mg/dl)

45.34 ± 11.05

49.45 ± 18.65

0.398

48.55 ± 15.12

47.47 ± 19.35

0.228

BMI (kg/m2)

29.37 ± 6.78

29.59 ± 3.62

0.421

31.78 ± 7.52

33.88 ± 2.89

0.166

QALY

      

EQ-5D-3 L

0.59 ± 0.03

0.73 ± 0.04

0.031

0.64 ± 0.11

0.66 ± 0.06

0.082

VAS

0.61 ± 0.05

0.75 ± 0.06

0.026

0.69 ± 0.04

0.71 ± 0.08

0.074

  1. Abbreviations: BIAsp biphasic insulin aspart 30, NPH/Reg NPH plus regular human insulin, HbA1c hemoglobin A1c, TG triglyceride, Chol cholesterol, LDL low density lipoprotein, HDL high density lipoprotein, BMI body mass index, QALY quality adjusted life year, EQ-5D-3 L European quality of life-5 dimensions -3 levels, VAS and visual analogue scale